相关实验视频
Updated: May 8, 2025

04:16
Electrocardiogram Recordings in Anesthetized Mice using Lead II
Published on: June 20, 2020
12.5K
长QT和布鲁加达综合征患者的麻醉管理
1Department of Anesthesiology, University of Miami Miller School of Medicine, Miami, Florida, USA.
Current opinion in cardiology
|April 30, 2025
概括
麻醉师必须谨慎管理患有长QT综合征或布鲁加达综合征的患者,避免影响心脏离子通道的药物,以防止危险的失律.
科学领域:
- 心脏病学 心脏病学
- 麻醉学 麻醉学
- 遗传学 是一个遗传学.
背景情况:
- 遗传性心律失常症,如长QT综合征和布鲁加达综合征,增加了危及生命的腹腔心律失常的风险.
- 这些通道病变影响心脏离子通道功能,使个人易患心律不整.
研究的目的:
- 为麻醉科医生提供当代的洞察力,帮助他们管理患有长QT综合征或布鲁加达综合征的患者.
- 突出这些患者群体中麻醉相关的潜在药物相互作用.
主要方法:
- 关于长QT综合征和布鲁加达综合征的当前文献的综述.
- 分析药物对心脏离子通道的影响和作用潜力的再极化.
主要成果:
- 长QT综合征涉及由于或通道障碍而延长的复极化;必须避免使用延长作用潜力的药物.
- 布鲁加达综合征是由致病性通道缺陷引起的;应避免服用加剧心电图变化的药物.
结论:
- 麻醉师需要了解长QT或布鲁加达病理的儿科患者的适当管理策略.
- 了解多药对心脏离子通道的影响对于安全麻醉至关重要.
更多相关视频
相关概念视频
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
1.0K
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
1.0K
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
805
Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of...
805
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
640
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
640
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
671
Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
671
Depolarizing Blockers: Pharmocokinetics
286
Depolarizing blockers are administered through intravenous injection. Succinylcholine is the most common choice of depolarizing blockers in emergency clinical practices. Although they have a rapid onset, they readily diffuse away from the motor end plate into the extracellular fluid. They are metabolized by enzymes such as liver butyrylcholinesterase and plasma pseudocholinesterases. This produces a short duration of action, typically 5-10 minutes long, unlike nondepolarizing blockers, which...
286
Nondepolarizing (Competitive) Neuromuscular Blockers: Pharmacological Actions
350
Nondepolarizing neuromuscular blockers prevent the membrane depolarization of muscle cells and inhibit muscle contraction. These are usually administered with anesthetics to achieve complete muscle relaxation. Upon administration, these drugs first block the small, rapidly contracting muscles of the face and hands, followed by the larger muscles of the trunk and the intercostal muscles. The diaphragm is the last muscle to be affected.
Although all competitive neuromuscular blockers are designed...
Although all competitive neuromuscular blockers are designed...
350

